EpiFrontier Therapeutics, Inc.

About EpiFrontier Therapeutics, Inc.

EpiFrontier is a biotechnology company focused on developing oral therapies for hemoglobinopathies, with a primary focus on Sickle Cell Disease (SCD). Their mission is to deliver accessible treatments worldwide, including to regions with limited healthcare resources, through breakthrough epigenetic therapeutics designed to increase fetal hemoglobin (HbF).

Products & Services

EPF-001:A potent and selective oral G9a (EHMT2) inhibitor designed to upregulate fetal hemoglobin expression through targeted epigenetic modulation, aiming to provide durable, disease-modifying benefits for SCD and potentially other hemoglobinopathies like β-thalassemia.

Specialties

Epigenetic Therapeutics Hemoglobinopathies Sickle Cell Disease Fetal Hemoglobin Modulation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 32000000 MR: - FA: up to $32 million FAN: 32000000	D: 2026-03-24 FD: 2026-03-24	2 investors

Grant Latest

2026-03-24

$32.0M

2 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Bruce Goldsmith

CEO

I

Ian Hardy

COO

K

Kenji Kishii

Japan Head

A

Azusa Shiohara

Board Member

A

Atsusuhi Usami

Board Member

A

Akihiro Ito

Founder/Advisor

View 7 more team members with Pro

Unlock Full Team Directory

Recent News